Skip to main content

Drug Interactions between pegulicianine and Uro-458

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

sodium biphosphate phenyl salicylate

Applies to: Uro-458 (hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium biphosphate) and Uro-458 (hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium biphosphate)

The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing. It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.

Bowel cleansing with sodium biphosphate can cause kidney failure, in some cases up to several months after the procedure. Although it rarely occurs, the risk is increased in individuals receiving treatment with phenyl salicylate, especially if they are also elderly or frail. You may need a dose adjustment or special tests to safely use both medications. Combining these medications may also increase the risk of dehydration and electrolyte abnormalities. In severe cases, dehydration and electrolyte abnormalities can lead to irregular heart rhythm, seizures, and kidney problems. You should use sodium biphosphate exactly as prescribed by your doctor, and drink plenty of clear fluids before, during, and after the cleansing process to keep yourself hydrated. Your doctor may also recommend an electrolyte rehydration solution that you can use. Talk to your doctor if you have any concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Major

methylene blue pegulicianine

Applies to: Uro-458 (hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium biphosphate) and pegulicianine

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with blue and possibly other dyes used for sentinel lymph node (SLN) mapping procedures may reduce the efficacy of pegulicianine imaging. The proposed mechanism is interference with the fluorescent signal from pegulicianine by the dye. Blue dyes have been demonstrated to fluoresce at the same wavelengths as the active metabolites of pegulicianine, which may reduce its capacity to produce the fluorescent signal that is used to differentiate cancerous tissue from normal cells. Concomitant use of any dye for SLN mapping on the day of surgery prior to imaging the lumpectomy cavity was listed in the exclusion criteria in clinical trials evaluating pegulicianine; hence, clinical data are not available.

MANAGEMENT: Administration of dyes for sentinel lymph node (SLN) mapping procedures should generally be avoided prior to imaging the lumpectomy cavity in patients receiving pegulicianine.

References

  1. (2024) "Product Information. Lumisight (pegulicianine)." Lumicell, Inc.
  2. Pellini F, Bertoldi L, deguidi g, et al. (2022) "The use of indocyanine green as the only tracer for the identification of the sentinel lymph node in breast cancer: safety and feasibility." Gland Surg, 11, p. 1139-47
  3. Nagao T, Kinoshita T, Hojo T, Kurihara H, tsuda h (2012) "Sentinel lymph node biopsy using indigo carmine blue dye and the validity of '10% rule' and '4 nodes rule.'" Breast, 21, P455-8
  4. Lumicell, Inc. (2024) Investigation of novel surgical imaging for tumor excision (INSITE). https://clinicaltrials.gov/study/NCT03686215
  5. Smith BL, hunt kk, Carr D, et al. (2024) Intraoperative fluorescence guidance for breast cancer lumpectomy surgery. https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200333#ap1
View all 5 references

Drug and food interactions

Moderate

sodium biphosphate food

Applies to: Uro-458 (hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium biphosphate)

Oral medications may not be properly absorbed when they are taken within one hour before starting sodium biphosphate for bowel cleansing. Talk to your doctor or pharmacist to see if you should adjust the dosing schedule of your other medications before you begin bowel cleansing treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

hyoscyamine food

Applies to: Uro-458 (hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium biphosphate)

Ask your doctor before using hyoscyamine together with ethanol. Use alcohol cautiously. Alcohol may increase drowsiness and dizziness while you are taking hyoscyamine. You should be warned not to exceed recommended dosages and to avoid activities requiring mental alertness. If your doctor prescribes these medications together, you may need a dose adjustment to safely take this combination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.